For example, the cancer treatment with “free” immunostimulatory anti-CD137 and interleukin (IL)-2 Fc fusion protein can enhance immune responses and improve anti-tumor activity, but at the same time, it can induce intolerable toxicity [52,53]. This evidence concerns the gene TNFRSF9 and neoplasm.